stockrow
Saturday 7 November 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
- EPS
- +30.2%
- Free cash flow
- −13.2%
Quarter to September 2026, against a year earlier
0.36
0.04
+12.50%
Follow TNYA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(83.84%) | (73.59%) | (121.86%) | (148.16%) | |
| (67.90%) | (59.50%) | (95.61%) | (112.05%) | ||
ROIC |
(256.77%) | (212.08%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(76.89%) | (78.50%) | (148.41%) | (190.79%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.30) | (0.24) | (0.24) | |
Free Cash Flow |
(68.88) | (64.63) | (52.59) | (54.62) | |
Capital Expenditures |
(0.62) | (0.25) | (0.26) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(30.78%) | (34.55%) | (35.65%) | (45.02%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.75 | 0.78 | 0.51 | 0.53 | |
Depreciation/Fixed assets |
0.32 | 0.31 | 2.91 | 5.00 | |
Capex/Depreciation |
(0.07) | (0.03) | (0.04) | (0.04) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.30) | (0.24) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026